Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 19c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($0.09), $0.19 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $71.3 million versus the consensus estimate of $54.72 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy
• JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS